a chest x-ray, whilst 27% of trainees stated they would not investigate further. Treatment options included oxygen, salbutamol, ipratropium, 0.9% saline drops or nebulisers, 3% saline nebulisers or not doing anything at all.

It appears that trainees are less confident at differentiating episodic viral wheeze from multi-trigger wheeze. 49% of trainees stated they would be give prednisolone to children with a first episode of viral wheeze. Trainees used different cut-off levels of oxygen saturations to initiate oxygen therapy. 69% of trainees felt that recurrent episodes of multi-trigger wheeze warranted regular inhaled beclomethasone, whilst 15% felt that montelukast was more appropriate. The need for an asthma action plan and asthma clinic follow up was raised by 85% and 76% of trainees respectively.

We sought to assess the knowledge of trainees on predisposing factors for early-onset multi-trigger wheeze. The two most predictive risk factors are a personal history of eczema, and a family history of asthma in mum or dad, which were identified by 78% and 59% of trainees respectively.

Conclusions There is a marked variation in how paediatric trainees deal with childhood wheeze. Rationalising investigations and therapeutic measures in bronchiolitis is associated with cost savings. Commonly used steroids are well known to have side-effects and should only be used where indicated. Local and national guidelines on childhood wheeze should aim to standardise practice across the UK for paediatric trainees, and reduce the financial burden on the NHS.

M28 RESPIRATORY CLINICIANS' EXPERIENCES OF END-OF-LIFE CARE IN IDIOPATHIC PULMONARY FIBROSIS

B Turmpenny, K Shepherd, Z Borrill. *Pennine Acute NHS Trust, Manchester, UK*

10.1136/thoraxjnl-2015-207770.455

Introduction Referral rates to Specialist Palliative Care are low in Idiopathic Pulmonary Fibrosis (IPF) despite mean survival of 3 years,¹ and a high symptom burden in the final year, in particular dyspnoea, chest pain, anxiety and depression, and fatigue.² This study aimed to explore chest clinicians' experiences in delivering care in advanced IPF.

Methods Questionnaires were distributed at a regional Respiratory meeting, focussing on initiating End-of-Life discussions, predicting prognosis, training, and reasons for low palliative care referrals.

Results 57 completed questionnaires - 17 chest consultants, 28 chest registrars, 11 physiotherapists, and 1 nurse clinician. 23 (40%) initiated End-of-Life discussions in severe IPF frequently or very frequently, and 47 (84%) felt it was a very important or important part of their role, but 42% felt predicting prognosis in advanced IPF was difficult or very difficult. More consultants felt End-of-Life discussions were an important part of their role than registrars.

Several aspects of End-of-Life care were felt to be harder in severe IPF than advanced malignancy (Figure 1), although similar to advanced COPD. 22 (42%) referred patients with severe IPF to hospital palliative care services very frequently or frequently, and 19 (37%) to community palliative care very frequently or frequently. Less than 10% of all respondents felt they had significant training in initiating End-of-Life discussions, palliating symptoms, or services available.

Clinicians' difficulty in IPF compared to Advanced Malignancy

Abstract M28 Figure 1

The three symptoms perceived to be experienced most in patients dying with IPF were breathlessness, anxiety and fatigue (cohort data supports this²). The three commonest reasons for low palliative care referrals were healthcare team perceptions that palliative care services focussed on cancer, patient's lack of awareness of prognosis, and difficulty clinicians have in predicting prognosis.

Conclusion Chest clinicians find predicting prognosis in ILD difficult, and this contributes to low palliative care referrals. They have minimal training in End-of-Life issues in IPF and there is a lack of local services for such patients. Respiratory training, and commissioning groups, are challenged to develop better End-of-Life services for a condition carrying a high symptom burden and often distressing death.

REFERENCES

- 1 Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. *Chest*. 1998;**113**:396–400
- 2 Bajwah S, Higginson IJ, Ross JR. *et al*. Specialist palliative care is more than drugs: a retrospective study of ILD patients. *Lung*. 2012;**190**:215–20

M29 TRYING TO CAUSE LESS PAIN FOR OUR PATIENTS! USING LOCAL ANAESTHESIA FOR ARTERIAL BLOOD GAS SAMPLING

N Maningo, S Chaudhry, A Parwaiz, B Suwal, RA Evans, RH Green, I Valero-Sanchez. *University Hospitals of Leicester NHS Trust, Leicester, UK*

10.1136/thoraxjnl-2015-207770.456

Background Direct radial artery puncture (DRAP) is considered the gold standard procedure for arterial blood gas (ABG) sampling, but it is associated with significant pain. The current 'BTS guidelines for oxygen use in adult patients' recommend using local anaesthesia (LA) for all ABG sampling except in emergency situations. LA can be administered subcutaneously or topically.

Aims

1. To assess the attitudes towards LA for ABG sampling in a population of medical junior doctors (JD).
2. To assess the effectiveness of topical lidocaine cream for ABG sampling by DRAP for respiratory inpatients.